Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharma Eight Starts New Drug Seeds Discovery in Okinawa
December 13, 2010
- Sanofi-aventis Completes Collection of PMS Case Report Forms for Lantus
December 13, 2010
- Major Drugstore Chain Operators Start Offering Points for Copayments for Dispensing Services
December 13, 2010
- OncoTherapy, Immunovaccine Enter Cancer Vaccine Research Agreement
December 13, 2010
- 79 Investigational Drugs for Alzheimer's Disease in Clinical Stage: PhRMA Report
December 13, 2010
- Astellas to Transfer Marketing of Protopic to Maruho
December 13, 2010
- Axitinib Extends PFS in mRCC Patients: Pfizer
December 13, 2010
- Ketotifen to Be Reclassified as Class 2 OTC Drug
December 13, 2010
- Takeda Licenses Baxter's Vero-Cell Based Flu Vaccine Technology
December 13, 2010
- BMS Confirms Non-Inferiority of SC Injection of Orencia
December 13, 2010
- Merck Serono Aims at 15% Growth in 2010-2014: President Smith
December 13, 2010
- Shionogi Licenses Ophthalmic Peptide Vaccines from OncoTherapy
December 13, 2010
- BIBF1120 Inhibits Lowering of FVC: BI
December 13, 2010
- NBI Takes Over Mobic Marketing from Daiichi Sankyo
December 13, 2010
- Lubiprostone Shows Favorable Safety, Tolerability in PIII: Sucampo, Abbott
December 13, 2010
- Sales of Class 1 OTC Drugs Up 8.9% in October: JSMI
December 13, 2010
- Otsuka HD's Market Capitalization to Exceed \1 Tril.
December 13, 2010
- JPMA Campaign Highlights Non-approved Drugs
December 13, 2010
- Kyorin Turns Down New Proposal from Sawai
December 13, 2010
- Daiichi Sankyo, Kitasato to Set Up Vaccine JV
December 13, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…